Frontline nilotinib in patients with chronic myeloid leukemia in chronic phase: Results from the European ENEST1st study

Leukemia

Volumn 30, Issue 1, 2016, Pages 57-64

  Hochhaus, A ^a   Rosti, G ^b   Cross, N C P ^c   Steegmann, J L ^d   Le Coutre, P ^e   Ossenkoppele, G ^f   Petrov, L ^g   Masszi, T ^h   Hellmann, A ⁱ   Griskevicius, L ^j   Wiktor Jedrzejczak, W ^k   Rea, D ^l   Coriu, D ^m   Brummendorf T H ⁿ   Porkka, K ^o   Saglio, G ^p   Gastl, G ^q   Muller M C ^r   Schuld, P ^s   Di Matteo, P ^t   Pellegrino, A ^t   Dezzani, L ^t   Mahon, F X ^u   Baccarani, M ^b   Giles, F J ^v   more..

^a JENA UNIVERSITY HOSPITAL   (Germany)

^b UNIVERSITY OF BOLOGNA   (Italy)

^c UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^d HOSPITAL UNIVERSITARIO DE LA PRINCESA   (Spain)

^e CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^f VU UNIVERSITY AMSTERDAM   (Netherlands)

^g Institute of Oncology Prof Dr Ion Chiricuta Cluj Napoca   (Romania)

^h Szent Laszlo Hospital   (Hungary)

ⁱ MEDICAL UNIVERSITY OF GDANSK   (Poland)

^j VILNIUS UNIVERSITY   (Lithuania)

^k MEDICAL UNIVERSITY OF WARSAW   (Poland)

^l SAINT LOUIS HOSPITAL   (France)

^m FUNDENI CLINICAL INSTITUTE   (Romania)

ⁿ UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

^o UNIVERSITY OF HELSINKI   (Finland)

^p UNIVERSITY OF TURIN   (Italy)

^q INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^r UNIVERSITY OF HEIDELBERG   (Germany)

^s NOVARTIS PHARMA AG   (Switzerland)

^t Novartis Oncology Region Europe   (Italy)

^u UNIVERSITÉ DE BORDEAUX   (France)

^v Northwestern University ^*  (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BCR ABL PROTEIN; GLUCOSE; HYDROXYUREA; IMATINIB; LIPID; NILOTINIB; 4-METHYL-N-(3-(4-METHYLIMIDAZOL-1-YL)-5-(TRIFLUOROMETHYL)PHENYL)-3-((4-PYRIDIN-3-YLPYRIMIDIN-2-YL)AMINO)BENZAMIDE; BCR-ABL1 FUSION PROTEIN, HUMAN; PROTEIN KINASE INHIBITOR; PROTEIN TYROSINE KINASE; PYRIMIDINE DERIVATIVE;

ADULT; AGED; ARTICLE; CANCER SURVIVAL; CHRONIC MYELOID LEUKEMIA; DRUG EFFICACY; FEMALE; FLUID RETENTION; HEADACHE; HEART ARRHYTHMIA; HUMAN; LIVER TOXICITY; MALE; METAPHASE; MULTIPLEX POLYMERASE CHAIN REACTION; NEUTROPENIA; OVERALL SURVIVAL; PANCREATITIS; PLEURA EFFUSION; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PRURITUS; RASH; SIDE EFFECT; THROMBOCYTOPENIA; TREATMENT DURATION; ADOLESCENT; ANTAGONISTS AND INHIBITORS; CLINICAL TRIAL; GENETICS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; PHASE 3 CLINICAL TRIAL; VERY ELDERLY;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; FEMALE; FUSION PROTEINS, BCR-ABL; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MALE; MIDDLE AGED; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES; PYRIMIDINES;

EID: 84953351161     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2015.270     Document Type: Article

References (35)

1. Tasigna [package insert]. Novartis Pharmaceuticals Corporation: East Hanover, NJ, USA, 2015.
2. Hughes TP, Saglio G, Kantarjian HM, Guilhot F, Niederwieser D, Rosti G et al. Early molecular response predicts outcomes in patients with chronic myeloid leukemia in chronic phase treated with frontline nilotinib or imatinib. Blood 2014; 123: 1353-1360.
3. Larson RA, Hochhaus A, Hughes TP, Clark RE, Etienne G, Kim DW et al. Nilotinib vs imatinib in patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: ENESTnd 3-year follow-up. Leukemia 2012; 26: 2197-2203.
4. Kantarjian HM, Hochhaus A, Saglio G, De Souza C, Flinn IW, Stenke L et al. Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial. Lancet Oncol 2011; 12: 841-851.
5. Saglio G, Kim DW, Issaragrisil S, le Coutre P, Etienne G, Lobo C et al. Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N Engl J Med 2010; 362: 2251-2259.
6. Hughes TP, Larson RA, Kim DW, Issaragrisil S, le Coutre PD, Lobo C et al. Efficacy and safety of nilotinib vs imatinib in patients with newly diagnosed chronic myeloid leukemia in chronic phase: 6-year follow-up of ENESTnd. Haematologica 2015; 100: 61, (abstract P228).
7. Hughes TP, le Coutre PD, Jootar S, Reiffers J, Turkina AG, Saglio G et al. ENESTnd 5-year follow-up: continued benefit of frontline nilotinib (NIL) compared with imatinib (IM) in patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP). Haematologica 2014; 99: 236-237 (abstract S677).
8. Mahon FX, Rea D, Guilhot J, Guilhot F, Huguet F, Nicolini F et al. Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial. Lancet Oncol 2010; 11: 1029-1035.
9. Ross DM, Branford S, Seymour JF, Schwarer AP, Arthur C, Yeung DT et al. Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study. Blood 2013; 122: 515-522.
10. Rousselot P, Charbonnier A, Cony-Makhoul P, Agape P, Nicolini FE, Varet B et al. Loss of major molecular response as a trigger for restarting tyrosine kinase inhibitor therapy in patients with chronic-phase chronic myelogenous leukemia who have stopped imatinib after durable undetectable disease. J Clin Oncol 2014; 32: 424-430.
11. Rea D, Nicolini FE, Tulliez M, Rousselot P, Guilhot F, Gardembas M et al. Dasatinib or nilotinib discontinuation in chronic phase (CP)-chronic myeloid leukemia (CML) patients (pts) with durably undetectable BCR-ABL transcripts: interim analysis of the STOP 2G-TKI study with a minimum follow-up of 12 months-on behalf of the French CML Group Filmc. Blood 2014; 124: (abstract 811).
12. Mahon FX, Baccarani M, Mauro MJ, Hughes TP, Saglio G, Savona M et al. Treatment-free remission (TFR) following nilotinib (NIL) in patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP): ENESTfreedom, ENESTop, ENESTgoal, and ENESTpath. J Clin Oncol 2014; 32: (abstract TPS7124).
13. Mahon FX, Richter J, Guilhot J, Muller MC, Dietz C, Porkka K et al. Interim analysis of a pan European Stop Tyrosine Kinase Inhibitor trial in chronic myeloid leukemia: the EURO-SKI study. Blood 2014; 124: (abstract 151).
14. Hasford J, Baccarani M, Hoffmann V, Guilhot J, Saussele S, Rosti G et al. Predicting complete cytogenetic response and subsequent progression-free survival in 2060 patients with CML on imatinib treatment: the EUTOS score. Blood 2011; 118: 686-692.
15. Cross NC, Melo JV, Feng L, Goldman JM. An optimized multiplex polymerase chain reaction (PCR) for detection of BCR-ABL fusion mRNAs in haematological disorders. Leukemia 1994; 8: 186-189.
16. Cross NCP, White H, Müller MC, Saglio G, Hochhaus A. Standardized definitions of molecular response in chronic myeloid leukemia. Leukemia 2012; 26: 2172-2175.
17. National Cancer Institute. NCI Common Terminology Criteria for Adverse Events (CTCAE), Version 4.0. National Cancer Institute: Bethesda, MD, USA, 2009.
18. Hehlmann R, Müller MC, Lauseker M, Hanfstein B, Fabarius A, Schreiber A et al. Deep molecular response is reached by the majority of patients treated with imatinib, predicts survival, and is achieved more quickly by optimized high-dose imatinib: results from the randomized CML-Study IV. J Clin Oncol 2014; 32: 415-423.
19. Etienne G, Dulucq S, Nicolini FE, Morrisset S, Fort MP, Schmitt A et al. Achieving deeper molecular response is associated with a better clinical outcome in chronic myeloid leukemia patients on imatinib front-line therapy. Haematologica 2014; 99: 458-464.
20. Falchi L, Kantarjian HM, Wang X, Verma D, Quintás-Cardama A, O'Brien S et al. Significance of deeper molecular responses in patients with chronic myeloid leukemia in early chronic phase treated with tyrosine kinase inhibitors. Am J Hematol 2013; 88: 1024-1029.
21. Castagnetti F, Gugliotta G, Breccia M, Stagno F, Iurlo A, Albano F et al. Long-term outcome of chronic myeloid leukemia patients treated frontline with imatinib. Leukemia 2015; 29: 1823-1831.
22. Kalmanti L, Saussele S, Lauseker M, Müller MC, Dietz CT, Heinrich L et al. Safety and efficacy of imatinib in CML over a period of 10 years: data from the randomized CML-study IV. Leukemia 2015; 29: 1123-1132.
23. Cross NCP, White HE, Colomer D, Ehrencrona H, Foroni L, Gottardi E et al. Laboratory recommendations for scoring deep molecular response following treatment for chronic myeloid leukemia. Leukemia 2015; 29: 999-1003.
24. Hoffmann VS, Baccarani M, Hasford J, Lindoerfer D, Burgstaller S, Sertic D et al. The EUTOS population-based registry: incidence and clinical characteristics of 2904 CML patients in 20 European countries. Leukemia 2015; 29: 1336-1343.
25. Hanfstein B, Müller MC, Hehlmann R, Erben P, Lauseker M, Fabarius A et al. Early molecular and cytogenetic response is predictive for long-term progression-free and overall survival in chronic myeloid leukemia (CML). Leukemia 2012; 26: 2096-2102.
26. Jabbour E, Kantarjian HM, Saglio G, Steegmann JL, Shah NP, Boqué C et al. Early response with dasatinib or imatinib in chronic myeloid leukemia: 3-year follow-up from a randomized phase 3 trial (DASISION). Blood 2014; 123: 494-500.
27. Marin D, Ibrahim AR, Lucas C, Gerrard G, Wang L, Szydlo RM et al. Assessment of BCR-ABL1 transcript levels at 3 months is the only requirement for predicting outcome for patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors. J Clin Oncol 2012; 30: 232-238.
28. Baccarani M, Deininger MW, Rosti G, Hochhaus A, Soverini S, Apperley JF et al. European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. Blood 2013; 122: 872-884.
29. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Chronic Myelogenous Leukemia, v1., National Comprehensive Cancer Network: Fort Washington, PA, USA, 2015.
30. Hanfstein B, Shlyakhto V, Lauseker M, Hehlmann R, Saussele S, Dietz C et al. Velocity of early BCR-ABL transcript elimination as an optimized predictor of outcome in chronic myeloid leukemia (CML) patients in chronic phase on treatment with imatinib. Leukemia 2014; 28: 1988-1992.
31. Branford S, Yeung DT, Parker WT, Roberts ND, Purins L, Braley JA et al. Prognosis for patients with CML and 410% BCR-ABL1 after 3 months of imatinib depends on the rate of BCR-ABL1 decline. Blood 2014; 124: 511-518.
32. Steegmann JL, Casado Montero LF, Gómez-Casares MT, Rozman M, Echeveste MA, Garcia-Gutierrez V et al. Very early molecular responses in the first two months of therapy are highly predictive of deep molecular responses at 18 months, in chronic myeloid leukemia patients treated upfront with nilotinib. Haematologica 2014; 99: 75 (abstract P281).
33. Marsh RW, Talamonti MS, Katz MH, Herman JM. Pancreatic cancer and FOLFIRINOX: a new era and new questions. Cancer Med 2015; 4: 853-863.
34. Welsh SJ. Corrie PG. Management of BRAF and MEK inhibitor toxicities in patients with metastatic melanoma. Ther Adv Med Oncol 2015; 7: 122-136.
35. Dooley AJ, Gupta A, Bhattacharyya M, Middleton MR. Intermittent dosing with vemurafenib in BRAF V600E-mutant melanoma: review of a case series. Ther Adv Med Oncol 2014; 6: 262-266.